Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly.

Laura E DichtelAllison KimballKevin C J YuenWhitney WoodmanseeMelanie S HainesQiu Xia GuanBrooke SwearingenLisa B NachtigallNicholas A TritosJulie L SharplessUrsula B KaiserAnu V GerweckKaren K Miller

Published in: Clinical endocrinology (2020)

Our data support a comparable QoL in patients receiving pegvisomant vs somatostatin analogs, despite the fact that the vast majority receiving pegvisomant did not respond to or were not able to tolerate somatostatin analogs.

Keyphrases

growth hormone
neuroendocrine tumors
molecular docking
binding protein
data analysis